EP Patent
EP2893919B1 — Formulation of aprepitant with enhanced solubility
Assigned to Zentiva KS · Expires 2017-07-12 · 9y expired
What this patent protects
Patent listed against Emend.
Drugs covered by this patent
- Emend (APREPITANT) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.